344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

Authors :: Anja J N H Timmer-Bonte
E A Bone
C.M.L. van Herpen
L. Hooftman
Ingrid M.E. Desar
Jaap Verweij
F. Eskens
M.J.A. de Jonge
Source :: European Journal of Cancer Supplements. 6:109
Publication Year :: 2008
Publisher :: Elsevier BV, 2008.

Subjects :: Cancer Research
Treatment refractory
Aminopeptidase inhibitor CHR-2797
business.industry
Pharmacology
chemistry.chemical_compound
Oncology
Tolerability
Paclitaxel
chemistry
Dose escalation
Medicine
In patient
business

Full Text Access

Tools